EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial

Andrea J Bullock, Benjamin L Schlechter, Marwan G Fakih, Apostolia M Tsimberidou, Joseph E Grossman, Michael S Gordon, Breelyn A Wilky, Agustin Pimentel, Daruka Mahadevan, Ani S Balmanoukian, Rachel E Sanborn, Gary K Schwartz und 16 weitere

Nature Medicine · 2024-09 · 30 (9) · 2558-2567

DOI: 10.1038/s41591-024-03083-7 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Nature Medicine, online erschienen am 13.06.2024. Verfasst von Andrea J Bullock und 27 weiteren Autor:innen. Beteiligte Einrichtung: Beth Israel Deaconess Medical Center, Boston, MA, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Colorectal Neoplasms. Die Arbeit wurde bisher 165-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Microsatellite stable metastatic colorectal cancer (MSS mCRC; mismatch repair proficient) has previously responded poorly to immune checkpoint blockade. Botensilimab (BOT) is an Fc-enhanced multifunctional anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody designed to expand therapy to cold/poorly immunogenic solid tumors, such as MSS mCRC. BOT with or without balstilimab (BAL; anti-PD-1 antibody) is being evaluated in an ongoing expanded phase 1 study. The primary endpoint is safety and tolerability, which was evaluated separately in the dose-escalation portion of the study and in patients with MSS mCRC (using combined dose-escalation/dose-expansion data). Secondary endpoints include investigator-assessed RECIST version 1.1–confirmed objective response rate (ORR), disease control rate (DCR), duration of response (DOR) and progression-free survival (PFS). Here we present outcomes in 148 heavily pre-treated patients with MSS mCRC (six from the dose-escalation cohort; 142 from the dose-expansion cohort) treated with BOT and BAL, 101 of whom were considered response evaluable with at least 6 months of follow-up. Treatment-related adverse events (TRAEs) occurred in 89% of patients with MSS mCRC (131/148), most commonly fatigue (35%, 52/148), diarrhea (32%, 47/148) and pyrexia (24%, 36/148), with no grade 5 TRAEs reported and a 12% discontinuation rate due to a TRAE (18/148; data fully mature). In the response-evaluable population ( n = 101), ORR was 17% (17/101; 95% confidence interval (CI), 10–26%), and DCR was 61% (62/101; 95% CI, 51–71%). Median DOR was not reached (NR; 95% CI, 5.7 months–NR), and median PFS was 3.5 months (95% CI, 2.7–4.1 months), at a median follow-up of 10.3 months (range, 0.5–42.6 months; data continuing to mature). The combination of BOT plus BAL demonstrated a manageable safety profile with no new immune-mediated safety signals and encouraging clinical activity with durable responses. ClinicalTrials.gov identifier: NCT03860272 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedColorectal NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsMicrosatellite InstabilityMicrosatellite RepeatsNeoplasm MetastasisNeoplasm Recurrence, Local

Substanzen

Antibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Dana-Farber Cancer Institute, Boston, MA, USA.
  • City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Agenus, Inc., Lexington, MA, USA.
  • HonorHealth Research Institute, Scottsdale, AZ, USA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Bullock, A. J., Schlechter, B. L., Fakih, M. G., Tsimberidou, A. M., Grossman, J. E., Gordon, M. S., Wilky, B. A., Pimentel, A., Mahadevan, D., Balmanoukian, A. S., Sanborn, R. E., Schwartz, G. K., Abou-Alfa, G. K., Segal, N. H., Bockorny, B., Moser, J. C., Sharma, S., Patel, J. M., Wu, W., …, & El-Khoueiry, A. B. (2024). Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial. Nature Medicine, 30(9), 2558-2567. https://doi.org/10.1038/s41591-024-03083-7

Vancouver

Bullock AJ, Schlechter BL, Fakih MG, Tsimberidou AM, Grossman JE, Gordon MS, et al. Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial. Nature Medicine. 2024;30(9):2558-2567. doi:10.1038/s41591-024-03083-7

BibTeX
@article{Bullock2024,
  author = {Bullock, Andrea J and Schlechter, Benjamin L and Fakih, Marwan G and Tsimberidou, Apostolia M and Grossman, Joseph E and Gordon, Michael S and Wilky, Breelyn A and Pimentel, Agustin and Mahadevan, Daruka and Balmanoukian, Ani S and Sanborn, Rachel E and Schwartz, Gary K and Abou-Alfa, Ghassan K and Segal, Neil H and Bockorny, Bruno and Moser, Justin C and Sharma, Sunil and Patel, Jaymin M and Wu, Wei and Chand, Dhan and Rosenthal, Katherine and Mednick, Gabriel and Delepine, Chloe and Curiel, Tyler J and Stebbing, Justin and Lenz, Heinz-Josef and O'Day, Steven J and El-Khoueiry, Anthony B},
  title = {Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial},
  journal = {Nature Medicine},
  year = {2024},
  volume = {30},
  number = {9},
  pages = {2558--2567},
  doi = {10.1038/s41591-024-03083-7}
}
Kostenlos starten →